Abstract. recent investigations discovered that cIApIn1 might be another drug resistance-associated molecule in cancer cells. However, the underlying mechanisms of cIApIn1-related multidrug resistance (MDr) remain elusive. In the present study, we investigated the role and possible mechanisms of cIApIn1 in MDr of human colon carcinoma loVo/Adr cells which express the wild-type p53 gene. By using small interference rnA and gene transfection techniques, we found that knockdown of cIApIn1 expression re-sensitized loVo/Adr cells to anti-cancer drugs and up-regulation of cIApIn1 in sensitive loVo cells resulted in a distinct MDr phenotype. We further revealed that cIApIn1 conferred the MDr phenotype in loVo/Adr cells through up-regulating expression of MDr-1 (p-gp) and Bcl-xl. Finally, by analyzing the effect of inactivation of wild-type p53 on cIApIn1-induced up-regulation of p-gp and Bcl-xl, we determined that cIApIn1 could exhibit its MDr-related function independently of the p53 signaling pathway. overall, the results presented here further suggest that over-expression of cIApIn1 is an important mechanism of drug resistance in human cancers, even if not the sole one.
Introduction
chemotherapy is the primary treatment for human cancer, but one clinically significant problem that often causes failure of chemotherapy is multidrug resistance (MDr). It is recognized that MDr arises from molecular changes, and a variety of mechanisms have been extensively studied in vivo and in vitro (1, 2) . However, the complete mechanisms involved in MDr have not been fully characterized, suggesting that there are still some unknown molecules and mechanisms responsible for MDr.
CIAPIN1 was initially identified as an apoptosis inhibitor with no homology to apoptosis regulatory molecules of the Bcl-2 family, caspase family or signal transduction molecules (3) . subsequently, Hao et al found that cIApIn1 was related to the MDr of gastric cancer sgc7901/Adr cells, and supposed that mutant p53-dependent signal pathway might be involved in the underlying mechanisms of cIApIn1-conferred MDr (4) . However, recently, li et al investigated the relationship between cIApIn1 expression and the MDr in leukemia Hl-60/Adr cells which has been determined to be a p53-null tumor cell line, and revealed that cIApIn1 was related to the MDr phenotype as well (5) . In this study, a wild-type p53 drug-resistant cell line loVo/Adr was selected as the experimental model (6) , and by this, we demonstrated that cIApIn1 can also confer the MDr phenotype in loVo/Adr cells through a mechanism involving up-regulation of MDr-1 (p-gp) and Bcl-xl. Further, we investigated the role of wildtype p53 in the cIApIn1-conferred MDr, and determined that in loVo/Adr cells cIApIn1 exhibits its MDr-related function independent of the p53 signaling pathway.
Materials and methods
Cell culture. Human colon carcinoma cell line loVo and the adriamycin-resistant counterpart loVo/Adr (both maintained in our laboratory) were used in this study. Details of the establishment and biological properties have been described (7) (8) (9) . the cells were routinely cultured in rpMI-1640 medium (life technologies, gaithersburg, MD) supplemented with 10% FBS (Life Technologies, Gaithersburg, MD) at 37˚C in a 5% co 2 incubator.
PCR analysis. total cell rnA was extracted using trIzol reagent (Invitrogen, UsA) according to the manufacturer's protocol. reverse transcription was performed on 1 µg of total rnA from each sample using revertAid™ First strand cDnA synthesis kit (Fermentas, canada). cIApIn1 cDnA was then amplified using the following primer pairs: forward, 5'-cggAAttcAtggcAgAttttgggAtctc-3'; reverse, 5'-ggtcgAcctAggcAtcAAgAttgctAtc-3'. ß-actin was used as the loading control. All pcr products were separated on ethidium bromide stained agarose gels and visualized with UV.
Immunocytochemistry assay. cells were cultured on glass cover slips for 24 h and fixed with 4% paraformaldehyde. The fixed cells were rinsed in PBS and permeabilized with 0.1% triton X-100 in pBs for 5 min. endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxide for 10 min and rinsed in pBs. the slips were incubated with anti-cIApIn1 primary mouse monoclonal antibody (developed by Hao et al) overnight at 4˚C (10) . Histostain™-Plus kits (Zhongshan, china) were used according to the manufacturer's instructions for detection of cIApIn1.
Western blot analysis. total cell lysate was prepared in 1X sDs buffer. proteins were separated by sDs-pAge and transferred onto pDVF membranes. Membranes were then blotted with antibodies to MDr-1 (p-gp), Bcl-2, Bax, p53 (Do-1) (santa cruz Biotechnology, santa cruz, cA), Bcl-xl (pharMingen, san Diego, cA), cIApIn1 (10) and ß-actin (sigma, st. louis, Mo). Antigen-antibody complexes were visualized with the enhanced chemiluminescence (Amersham pharmacia Biotech, piscataway, nJ).
Cell transfection. cells were planted on 6-well plates and cultured in drug-free medium. At 90-95% confluency, cells were washed twice with pBs and grown in 2 ml rpIM-1640 without antibiotics. Using lipofectamine™ 2000 reagent (Invitrogen, Inc., carlsbad, cA, UsA), 2 µg pcDnA3.1 (Invitrogen) which included the full-length cDnA for cIApIn1, or psip53 small interfering rnA (sirnA) plasmids was transfected into loVo cells, respectively, and 2 µg psicIApIn1 sirnA plasmids were transfected into loVo/Adr cells, as described previously (4, 11) . the cells that had been transfected with pcDnA3.1 vector alone or psilencer™ 3.1-H1 neo vector alone served as negative control. Forty-eight hours later, cells were placed in growth medium containing g418 (life Technologies) at a final concentration of 400 µg/ml for clone selection. the expression levels of cIApIn1 in g418-resistant stable clones were evaluated by Western blot analysis.
Clonogenic assay. cells were plated out at 5x10 5 cells per 100-mm dishes the day before treatment, and then treated with different concentrations of adriamycin (between 0 and 20 µg/ml) for ~4 h in growth medium, passaged 3 days later at very low density and further cultured for 10 days without medium renewal. At this time, cells were fixed and stained with a solution of crystal violet in methanol-acetic acid, and the numbers of clones per dish were counted. results are given as the calculated total number of cell clones that would have resulted from the plating of all the treated cells or as the calculated cloning efficiency (12) .
In vitro drug sensitivity assay. Drug sensitivity was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (Mtt) assay, as described previously (13) . Briefly, cells were trypsinized and diluted with culture medium to seeding density (10,000 cells per well), suspended in 96-well plates (200 µl/well, costar, cambridge, MA, UsA), and incubated at 37˚C for 24 h. Cells were then incubated for 72 h in the presence or absence of various concentrations of the four freshly prepared anti-cancer drugs (adriamycin, vincristine, 5-fluorouracil and mitomycin c) in 200 µl medium. each condition was assayed in triplicate. Following cell incubation for 72 h, 50 µl of 2 mg/ml Mtt (sigma) was added into each well, and cells incubated another 4 h. the supernatants were then discarded, and 150 µl DMso (sigma) was added into each well to dissolve crystals. Absorbance at 490 nm (A 490 ) was measured with a microplate reader (Bp800; Biohit, Helsinki, Finland). cell survival rates were calculated according to the following formula: survival rate = (mean A 490 of treated wells/mean A 490 of untreated wells) x 100%. Dose-response curves of the anti-cancer drugs were drawn on semilogarithmic coordinate paper, and Ic 50 values were determined. resistance index (rI) was calculated using the following formula: rI = Ic 50 for cIApIn1-related loVo transfectants/Ic 50 for control cells.
Intracellular drug accumulation assay. Fluorescence intensity of intracellular adriamycin was determined by flow cytometry as previously reported (14) . cells at log phase were trypsinized, resuspended and plated into 6-well plates at a cell density of 1x10 6 /well. After overnight culture at 37˚C, adriamycin was added to the medium at a final concentration of 5 µg/ml. the cells were incubated for 1 h, and then were harvested by trypsinization for the determination of adriamycin accumulation, or cultured with fresh, drugfree medium for another 30 min for the determination of adriamycin retention. the harvested cells were washed with ice-cold pBs, and intracellular adriamycin was detected by flow cytometry with an excitation wavelength of 488 nm and an emission wavelength of 575 nm. the experiment was performed independently 3 times. Finally, the adriamycinreleasing index of the colon carcinoma cells was calculated using the following formula: releasing index = (accumulation value-retention value)/accumulation value.
Reporter gene assay. loVo cells were seeded in 6-well plates and grown in maintenance medium. the pgl3-MDr-1 vector (promoter of MDr-1, -136 to +10) and the control vector were established previously (15) . Briefly, cells were co-transfected with indicated amounts of pcDnA3.1/ cIApIn1 plasmids (0.3, 0.6 and 0.9 µg), pgl3-MDr-1 and prl-tK vector using the Fugene transfection regent (roche, Indianapolis, In, UsA). After 48 h, luciferase reporter assays were performed according to the manufacturer's instruction (promega, Madison, WI, UsA). cells were then processed for ß-galactosidase staining with panVera ß-galactosidase staining kit, according to the manufacturer's protocols. A total of 300 cells per well was countered, and the percentage of blue cells were determined.
Annexin V staining. cells were washed twice with cold pBs and resuspended in 100 µl binding buffer at a concentration of 1x10 6 cells/ml. Annexin V-FItc (5 µl, pharMingen) and 10 of 20 µg/ml propidum iodide (sigma) were then added to the cells. After incubation at room temperature for 15 min, 400 µl Annexin-binding buffer was added to each sample, and the samples were kept on ice to counter the stained cells by flow cytometry (16) .
Statistical analysis. the data are expressed as the means ± sD. Differences were compared by one-way AnoVA analysis followed by lsD t-test. All statistical analyses were performed using spss11.0 software (chicago, Il, UsA). P<0.05 was considered as statistically significant.
Results
The expression of CIAPIN1 is higher in LoVo/Adr cells than in LoVo cells at both the mRNA and protein level. rt-pcr and Western blot analysis revealed both mrnA and protein levels of cIApIn1 were higher in loVo/Adr than that in loVo ( Fig. 1A and B) . cIApIn1 was widely expressed both in cytoplasm and nucleus (17) , and by immunocytochemistry (Fig. 1c) , we found that although immunostaining for cIApIn1 could be observed both in loVo/Adr and loVo cells, a much stronger staining was detected in the nucleus of loVo/Adr cells. of note, an intense accumulation of cIApIn1 within nucleolus was observed in loVo/Adr cells, whereas in loVo cells, it was low or even absent.
Knockdown of CIAPIN1 expression resensitized LoVo/ Adr cells to anti-cancer drugs. to explore the relationship between over-expression of cIApIn1 and the MDr phenotype, a sirnA eukaryotic expression vector of cIApIn1 (psicIApIn1) was transfected into loVo/Adr cells (loVo/ Adr-psicIApIn1) to examine whether down-regulation of cIApIn1 increased cell sensitivity towards anti-cancer drugs. As illustrated by Western blot analysis in Fig. 3e , cIApIn1 protein level in loVo/Adr-psicIApIn1 cells reduced pronouncedly compared with that of parental loVo/Adr cells. clonogenic assay showed that loVo/Adr-psicIApIn1 cells displayed an obvious decrease in resistance to adriamycin ( Fig. 2A) . Upon adriamycin exposure at 5 µg/ml for 4 h, it appeared that the cloning efficiency of LoVo/Adr-pSiCIAPIN1 cells was on average 9.1-fold lower than that of the control cells transfected with psilencer 3.1-H1 neo vector (loVo/Adr-psi) (p<0.05) (Fig. 2B) . Drug-sensitive assays in vitro revealed that down-regulation of cIApIn1 increased the sensitivity of loVo/Adr cells to three anti-cancer drugs with different mechanisms of action (p-gp-related drugs: adriamycin and vincristine, p<0.01; p-gp-unrelated drugs: mitomycin c and 5-fluorouracil, p<0.05, loVo/Adr-psicIApIn1 vs. loVo/ Adr-psi), which further suggested the MDr phenotype of loVo/Adr cells could be partially reversed by knockdown of cIApIn1 expression (table I) .
Up-regulation of CIAPIN1 in sensitive LoVo cells resulted in the MDR phenotype. previous studies showed that transfection of CIAPIN1 was sufficient to confer adriamycin and vincristine resistance to leukemia and gastric cancer cells (4, 5) . In the present study, drug-sensitive loVo cells were transfected with the recombinant plasmids containing the complete open reading frame of cIApIn1, and one stable clone with stable over-expression of cIApIn1 (loVopcIApIn1) was selected (Fig. 3e) . Fig. 2c showed the survival curve for adriamycin as analyzed by clonogenic assay. the rate of cell survival in loVo-pcIApIn1 (Fig. 2c  and D) , was significantly higher than that in LoVo-pc after exposure to ≥0.5 µg/ml adriamycin (p<0.05). Drug sensitivity assays in vitro showed that loVo-pcIApIn1 cells were 2.15-, 4.04-, and 8.58-fold more resistant relative to loVo-pc cells to the three anti-cancer drugs adriamycin, vincristine and mitomycin c, respectively, indicating that up-regulation of cIApIn1 could induce an obvious MDr phenotype in drug sensitive loVo cells (table I) . anti-cancer drugs by drug transporter p-gp is an important mechanism that confers the MDr phenotype in human cancers (1,2,18) , and previous studies have discovered that, compared with its parental loVo cells, the most distinguished character of loVo/Adr cells is the up-regulated expression of P-gp (7-9). In this experiment, we first estimated the expression changes of p-gp in cIApIn1-related loVo transfectants. Western blot analysis revealed that the expression level of p-gp relative to ß-actin was markedly higher in loVopcIApIn1 cells and lower in loVo/Adr-psicIApIn1 cells compared with the empty-vector-transfected control cells (Fig. 3e) . to test the relevance of this increase in p-gp expression to cIApIn1-associated drug resistance in loVo/Adr cells, we evaluated adriamycin accumulation and retention by flow cytometry in control and CIAPIN1-related transfectants. Adriamycin is fluorescent and this attribute provides easy monitoring of its intracellular accumulation and retention by flow cytometry. As shown in Fig. 3A , LoVo-pCIAPIN1 cells showed decreased adriamycin retention compared to loVo-pc cells, while, the adriamycin retention in loVo/ Adr-pSiCIAPIN1 cells was increased significantly compared to its control loVo/Adr-psi cells (p<0.05). consistent with this, loVo-pcIApIn1 cells showed increased releasing index, whereas LoVo/Adr-pSiCIAPIN1 cells decreased. To confirm that the differences in drug accumulation were due to p-gp activity, we performed similar assay in loVo-pcIApIn1 cells in the presence of verapamil, an inhibitor of p-gp activity (15) . As illustrated in Fig. 3B , verapamil could partially reduce the extrusion of adriamycin in loVo-pcIApIn1 cells.
cell lines -----------------------------------------------------------------------------------loVo/Adr loVo ---------------------------------------------------------------------------
luciferase reporter assay was further performed in loVo cells to investigate whether cIApIn1 conferred the MDr through regulation of p-gp. As shown in Fig. 3c , co-transfection of the MDr-1 (p-gp) reporter gene with increasing amounts of the cIApIn1 expression vector resulted in an essential liner increase in MDr-1 promoter activity, which suggested that cIApIn1 was involved in regulation of MDr-1 transcription in loVo/Adr cells. (1,2,19) . cIApIn1 was initially discovered as a novel anti-apoptotic molecule (3), suggesting that up-regulation of cIApIn1 might also contribute to the MDr phenotype through suppressing drug-induced apoptosis. In this study, to investigate whether cIApIn1 affected the capacity of loVo cells to undergo anti-cancer drugs induced apoptosis, Annexin V staining was performed. As revealed in Fig. 3D , the apoptosis index of LoVo-pCIAPIN1 cells was significantly lower than that of loVo-pc cells after treatment of 0.5 µg/ml adriamycin for 48 h (p<0.05), and on the other hand, loVo/Adr-psicIApIn1 cells showed increased apoptosis than that in its control loVo/ Adr-psi cells after treatment of 5 µg/ml adriamycin for 48 h (p<0.05).
CIAPIN1 increased the anti-apoptotic capacity of LoVo cells through up-regulation of Bcl-xL. suppression of drug-induced apoptosis is another important mechanism of MDr
For Bcl-2/Bax expression ratio is an important indicator of apoptosis (20), we tested the expression changes of the two molecules by Western blot analysis. As shown in Fig. 3e and F, expression of the anti-apoptotic protein Bcl-2 increased in response to up-regulation of cIApIn1 (p<0.05). Interestingly, we observed that the pro-apoptotic protein Bax was also slightly up-regulated in loVo-pcIApIn1 cells, for which, there was no significant alternation of Bcl-2/Bax ratio observed in response to up-regulation of cIApIn1 (p>0.05) (Fig. 3e  and F) . Because shibayama et al observed that expression of Bcl-xl was severely impaired in the cIApIn −/− mice (3), indicating that cIApIn1 might regulate the expression of Bcl-xl, we further tested the expression of Bcl-xl and found that expression of Bcl-xl in pcIApIn1-transfected loVo cells was greatly up-regulated (Fig. 3e) , suggested that cIApIn1 increased the anti-apoptotic capacity of loVo cells mainly through up-regulation of Bcl-xl.
CIAPIN1 conferred MDR in LoVo cells in a p53-independent
manner. In a previous study, li et al observed that, in p53 wild-type Hepg2 and sMMc-7721 cells, apoptosis induced by AdsicIApIn1 (adenovirus-delivered cIApIn1 small interfering rnA) partially resulted from accumulation of p53 protein, indicating cIApIn1 might inhibit the expression or accumulation of p53 (11) . For loVo cells is known to express wild-type p53 (6), we investigated the role of p53 in the cIApIn1-related MDr in present study. However, by Western blot analysis, we found that between loVo-pcIApIn1 and loVo cells there was no obvious difference in p53 protein level (Fig. 4A) . to elucidate whether cIApIn1-conferred MDr in loVo cells was p53-independent, we generated a loVo cell line stably expressing antisense p53 (loVo-psip53) (Fig. 4A) . As shown in Fig. 4B , inactivation of p53 in loVo cells could not overcome the cIApIn1-mediated expression changes of p-gp and Bcl-xl. Further, by intracellular drug accumulation assay, we revealed that, as well as that in loVo-psi cells, the adriamycin-releasing index in loVo-psip53 cells was significantly increased after exposure to Ad-CIAPIN1 (recombinant adenovirus expressing cIApIn1, constructed in our laboratory) (p<0.05, Fig. 4c ) (21) , indicating that exogenous cIApIn1 protein was of ability to up-regulate p-gp expression and induce corresponding drug resistance phenotype without functional p53 protein.
Discussion
Increased amounts of p-gp may confer MDr on cells by preventing the intracellular accumulation of a variety of cytotoxic drugs, including adriamycin, vincristine and etoposide. the multidrug-resistant loVo/Adr cells with wild-type p53 gene used in this study were selected by continuous exposure to adriamycin, whose classical phenotype was characterized by active drug extrusion due to p-gp over-expression (7) (8) (9) . cIApIn1 was found to be over-expressed in loVo/Adr cells and confer the MDr phenotype. to clarify the association of p-gp with cIApIn1-related MDr in loVo/Adr cells, we investigated the effects of cIApIn1 on the expression of p-gp and the MDr phenotype mediated by p-gp. By using gene transfection and small interference rnA techniques, we demonstrated that cIApIn1 could confer the MDr features of loVo/Adr cells through up-regulating the expression of p-gp.
suppression of drug-induced apoptosis is another important mechanism of MDr. By drug sensitivity assays, we revealed cIApIn1 also conferred the MDr of loVo/Adr cells to p-gp-unrelated drugs mitomycin c, which indicated that over-expressed cIApIn1 increased the anti-apoptotic capacity of loVo/Adr cells as well. However, as analyzed by Western blot, both the expression of anti-apoptotic protein Bcl-2 and apoptotic protein Bax increased in response to up-regulation of cIApIn1, and from which, the Bcl-2/Bax ratio was not altered significantly. This result was not paralleled by the changes in MDr phenotype of loVo-pcIApIn1 cells. therefore, we detected the expression of another anti-apoptotic protein Bcl-xl, and found it up-regulated in loVo-pcIApIn1 cells. shibayama et al reported that the expression of Bcl-xl and JAK2 was severely impaired in the cIApIn −/− mice, and hypothesized cIApIn1 might protect cells against apoptosis through regulation of JAK2/stAts pathway (3) . Although the significance of activation of the JAK2/stAts pathway remains under investigation, several reports have shown that phosphorylation and activation of JAK2 and stAt proteins appeared to play a critical role in regulating the expression of Bcl-2 family proteins in human cancer cells, including the loVo cells (22) (23) (24) . thus, the activation of JAK2/stAts pathway induced by cIApIn1 seems to be a reasonable explanation for the increased expression of Bcl-xl, Bcl-2 and Bax in loVo-pcIApIn1 cells.
loVo/Adr cells have been characterized as sensitive to 5-fluorouracil although displaying a cross-resistant phenotype to several anti-cancer drugs such as vincristine, Vp-16, cyclophosphamide and mitomycin c (9, 25) . In the present study, we also observed that up-regulation of cIApIn1 in loVo cells induced cross-resistance to vincristine and mitomycin c, but not to 5-fluorouracil. In theory, up-regulation of CIAPIN1 and consequent increased Bcl-xl expression should increase the capacity of LoVo cells to undergo 5-fluorouracil-induced apoptosis. However, observations are inconsistent with the presumption. Interestingly, several multidrug-resistant cell lines, including gastric cancer sgc7901/Adr cells, leukemia Hl-60/Adr cells, breast cancer McF/Adr cells, and colon cancer loVo/Adr cells, have been successfully selected by using similar methods that apply intermittent exposures to adriamycin. Among the four cell lines, sgc7901/Adr and leukemia Hl-60 with p53 dysfunction for mutation or depletion showed cross-resistance to 5-fluorouracil (26, 27) , whereas McF/Adr and loVo/Adr both with wild-type p53 was still sensitive to 5-fluorouracil (6, 25, 28) . It has been discovered that 5-FU-induced apoptosis was accompanied by increased expression of Bax and Bak without consistent modulation of other Bcl-2 family proteins in a p53 (wild-type)-dependent manner (29) . therefore, we may infer that the anti-apoptotic effect of Bcl-xl in loVo/Adr or loVo-pcIApIn1 cells is attenuated or eliminated by accompanied up-regulation of Bax and Bak in exposure to 5-fluorouracil.
Initially, Hao et al hypothesized that cIApIn1 might confer MDr in cancer cells via regulating the expression of mutant p53 (4). However, it is worth noting that, the status of p53 in the three tested cancer cells was different: loVo cells have p53 wild-type (6), sgc7901 cells are p53 mutant (27), and Hl-60 cells are p53 null (28) . therefore, cIApIn1 conferring MDr in cancer cells via regulating the expression of mutant p53 is not comprehensive. More recently, li et al found that down-regulation of cIApIn1 by adenovirusdelivered small interfering rnA could result in enhanced expression of p53 protein in Hepg2 and sMMc-7721 cells that contained wild-type p53 gene (11) . It seems reasonable that cIApIn1 mediated MDr in wild-type p53 loVo cells via inhibiting expression of p53 (30) . However, by silencing p53 expression and analyzing the effect of inactivation of p53 on the cIApIn1 induced up-regulation of p-gp and Bcl-xl, we excluded the possibility of cIApIn1 conferring MDr via p53 signal pathway in LoVo/Adr cells. This result further verified the fact that cIApIn1 could exhibit different functions in different genetic context in cell lines.
In conclusion, these results from our study further indicated that over-expression of cIApIn1 was the mechanism of drug resistance, in the human cancers studied, which might therefore be a new target for MDr reversal therapy.
